[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100385980":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":11,"centralContacts":11,"locations":34,"responsibleParty":81,"collaborators":85,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"University of Virginia","OTHER",[8,14,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Alanyl-glutamine 0g","PLACEBO_COMPARATOR",null,[13],"Drug: Alanyl-glutamine",{"label":15,"type":16,"description":11,"interventionNames":17},"Alanyl-glutamine 4g","EXPERIMENTAL",[13],{"label":19,"type":16,"description":11,"interventionNames":20},"Alanyl-glutamine 24g",[13],{"label":22,"type":16,"description":11,"interventionNames":23},"Alanyl-glutamine 44g",[13],[25],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Alanyl-glutamine","The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.",[9,19,22,15],[31,32,33],"Alagln","AQ","glutamine",[35,60],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"UVA Health Systems","RECRUITING","Charlottesville","Virginia","22903","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-78.47668,38.02931,{"lat":47,"lon":46},[50,55,59],{"name":51,"role":52,"phone":53,"phoneExt":11,"email":54},"Cirle Warren, M.D.","CONTACT","434-270-1082","CA6T@hscmail.mcc.virginia.edu",{"name":56,"role":52,"phone":57,"phoneExt":11,"email":58},"Darren Hackley, M.A., CCRP","540-613-2972","dan5kq@uvahealth.org",{"name":51,"role":52,"phone":11,"phoneExt":11,"email":11},{"facility":61,"status":37,"city":62,"state":39,"zip":63,"country":41,"countryCode":42,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Carilion Clinic","Roanoke","24014",{"type":44,"coordinates":65},[66,67],-79.94143,37.27097,{"lat":67,"lon":66},[70,74,78,79],{"name":71,"role":52,"phone":72,"phoneExt":11,"email":73},"Ekta Bansal, M.D.","540-200-9065","enbansal@carilionclinic.org",{"name":75,"role":52,"phone":76,"phoneExt":11,"email":77},"Ruth Ndolo, Ed.D, RN, CCRP","540-266-6557","rmndolo@carilionclinic.org",{"name":71,"role":52,"phone":11,"phoneExt":11,"email":11},{"name":80,"role":52,"phone":11,"phoneExt":11,"email":11},"Jazmine Jackson-Akers, D.O.",{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Cirle Warren, MD","Research Professor",[86,87],{"name":61,"class":6},{"name":88,"class":6},"University of Southampton","100385980","phase-2-alanyl-glutamine-supplementation-for-c-difficile-treatment-act-100385980",false,"NCT04305769","Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)","Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: a Randomized, Double-blind, Placebo-controlled Trial","ACT","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 18 years and older.\n4. Admitted to UVA hospital, or seen as an outpatient, or seen at Carilion hospital.\n5. Presence of diarrhea\\*\n6. Episode of C. difficile infection, non-severe or severe uncomplicated.\n7. Within 120 hours of receiving standard therapy (oral vancomycin or fidaoxmicin).\n8. Must be able to provide informed consent in person or electronically, or if not able to have a LAR to provide consent, in person or remotely via virtual or electronic means.\n\nExclusion Criteria:\n\n1. At enrollment, presence of any of the following:\n\n   1. Hypotension or shock\n   2. Megacolon or moderate to severe ileus\n   3. Acute abdomen\n   4. Admission to intensive care unit\n2. Inability to tolerate oral or enteral medication\n3. Presence of other known infectious etiology of diarrhea\n4. COVID-19 co-infection at the time of CDI diagnosis.\n5. Absolute neutrophil count \\\u003C500 mcl\n6. Within 100 days of hematologic or solid organ transplant\n\n   • Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) or other etiology of non-infectious diarrhea. For patients with history of IBD, allow enrollment if disease is well-controlled and stable (not in flare).\n7. Enrollment in another investigational drug trial\n8. Current use of alternative treatment for CDI (e.g. antibiotics other than vancomycin or fidaxomicin; IVIg; fecal transplant).\n9. On probiotics and not willing to discontinue.\n10. Cirrhosis or in participants with ALT \\> 3X normal\n11. End stage renal disease, unless on dialysis(HD or PD) or creatinine clearance or estimated GFR of \\\u003C30mL\u002Fmin even after adequate hydration\n12. Life expectancy of \\\u003C 6 months.","ALL","18 Years","105 Years",{"count":101,"type":102},260,"ESTIMATED","INTERVENTIONAL",[105],"PHASE2","This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident cases of uncomplicated C. difficile infection (CDI) in hospitalized, or outpatient, persons aged 18 or older. The investigators hypothesis is that alanyl-glutamine supplementation will decrease recurrence and mortality from CDI and these outcomes will be associated with improvement of inflammatory markers and restoration of intestinal microbiota function.",[108,109,110,111],"Clostridioides Difficile Infection","Clostridium Difficile Infection","Clostridium Difficile Diarrhea","Clostridia Difficile Colitis","2024-10-22",{"date":114,"type":115},"2024-10-26","ACTUAL",{"date":117,"type":115},"2021-06-01",{"date":119,"type":102},"2027-06-30",{"name":5,"class":6},2]